Appointment of Senior Medical Advisor

RNS Number : 3294Y

SkinBioTherapeutics PLC

08 September 2020

 

8 September 2020

SkinBioTherapeutics plc

Appointment of Senior Medical Advisor

SkinBioTherapeutics plc (AIM: SBTX or the "Company") a life sciences company focused on skin health, announces the appointment of Dr Jonathan Sheffield as a Senior Medical Advisor with immediate effect.

Jonathan formerly served as the CEO of the National Institute for Health Research (NIHR), Clinical Research Network since 2010. The Clinical Research Network delivers clinical research studies throughout the NHS in England covering primary, secondary and tertiary care. In 2018-19, the Network recruited over 902,000 patients into over 5,250 studies across the NHS.

Jonathan qualified as a doctor in 1981 and trained as a Histopathologist. He has subsequently held multiple senior medical management posts in the NHS at local, regional and national levels and was awarded an OBE for service to the NHS in 2009. Jonathan was elected an Honorary Fellow of the Royal College of Physicians' Faculty of Pharmaceutical Medicine in 2011 for his contribution in the area of clinical research delivery.

Stuart Ashman, CEO of SkinBioTherapeutics, said:

"Jonathan will bring to SkinBioTherapeutics broad clinical knowledge accumulated over his career. Having served as CEO of the Clinical Research Network for 10 years, he has the expertise and extensive network in clinical research that will be of critical importance to the Company as we progress our product development programmes."

Dr Jonathan Sheffield, Senior Medical Advisor at SkinBioTherapeutics, said:

"Throughout my career I have been passionate about innovative, ground-breaking science, and how medical knowledge can be advanced through clinical research to improve lives. SkinBioTherapeutics' technology is one that is grounded in compelling science and has the potential to make a material difference for patients in several areas through its multiple programmes. I look forward to getting to know the team and the technology over the coming months."

-Ends-

For more information please contact:

SkinBioTherapeutics plc	Tel: [phone]
Stuart Ashman, CEO Doug Quinn, CFO
Cenkos Securities plc (Nominated Adviser & Broker)	Tel: [phone]
Giles Balleny, Max Gould (Corporate Finance) Michael Johnson (Sales)
Instinctif Partners	Tel: [phone]
Melanie Toyne-Sewell / Phillip Marriage / Nathan Billis	[e-mail]

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company has demonstrated, through scientific testing, that the SkinBiotix® platform can improve the barrier effect of skin models, protect from infection and repair wounds. Proof of principle studies have also shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. The technology achieved positive results in clinical studies in human volunteers in early 2019.

The Company listed on AIM in April 2017 and is based in Manchester, UK.  For more information, visit:  www.skinbiotherapeutics.com . 

 

END

 

 

MSCGLGDCRBGDGGI